{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:00:03Z","timestamp":1793826003963,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["URGENCE COVID-19"],"award-info":[{"award-number":["URGENCE COVID-19"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-flash COVID-19"],"award-info":[{"award-number":["ANR-flash COVID-19"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-69-01"],"award-info":[{"award-number":["ANR-10-LABX-69-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Host immunity to infection with SARS-CoV-2 is highly variable, dictating diverse clinical outcomes ranging from asymptomatic to severe disease and death. We previously reported reduced type I interferon in severe COVID-19 patients preceded clinical worsening. Further studies identified genetic mutations in\n                    <jats:italic>loci<\/jats:italic>\n                    of the TLR3- or TLR7-dependent interferon-I pathways, or neutralizing interferon-I autoantibodies as risk factors for development of COVID-19 pneumonia. Here we show in patient cohorts with different severities of COVID-19, that baseline plasma interferon \u03b1 measures differ according to the immunoassay used, timing of sampling, the interferon \u03b1 subtype measured, and the presence of autoantibodies. We also show a consistently reduced induction of interferon-I proteins in hospitalized COVID-19 patients upon immune stimulation, that is not associated with detectable neutralizing autoantibodies against interferon \u03b1 or interferon \u03c9. Intracellular proteomic analysis shows increased monocyte numbers in hospitalized COVID-19 patients but impaired interferon-I response after stimulation. We confirm this by ex vivo whole blood stimulation with interferon-I which induces transcriptomic responses associated with inflammation in hospitalized COVID-19 patients, that is not seen in controls or non-hospitalized moderate cases. These results may explain the dichotomy of the poor clinical response to interferon-I based treatments in late stage COVID-19, despite the importance of interferon-I in early acute infection and may guide alternative therapeutic strategies.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-34895-1","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T16:32:27Z","timestamp":1669393947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Defective activation and regulation of type I interferon immunity\u00a0is associated with increasing COVID-19 severity"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-612X","authenticated-orcid":false,"given":"Nika\u00efa","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Poss\u00e9m\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-0984","authenticated-orcid":false,"given":"Vincent","family":"Bondet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7270-3838","authenticated-orcid":false,"given":"Jamie","family":"Sugrue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7089-0665","authenticated-orcid":false,"given":"Liam","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5478-482X","authenticated-orcid":false,"given":"Bruno","family":"Charbit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rouilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Saint-Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Dott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre Rodriguez","family":"Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Yatim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-1475","authenticated-orcid":false,"given":"Olivier","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minerva","family":"Cervantes-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bastard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Laurent","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali-Anne","family":"Szwebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0616-2874","authenticated-orcid":false,"given":"Cliona","family":"O\u2019Farrelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00edona N\u00ed","family":"Cheallaigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4313-6859","authenticated-orcid":false,"given":"Nollaig M.","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8875-2308","authenticated-orcid":false,"given":"Darragh","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"34895_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.coi.2022.01.003","volume":"74","author":"P Bastard","year":"2022","unstructured":"Bastard, P., Zhang, Q., Zhang, S.-Y., Jouanguy, E. & Casanova, J.-L. Type I interferons and SARS-CoV-2: from cells to organisms. Curr. Opin. Immunol. 74, 172\u2013182 (2022).","journal-title":"Curr. Opin. Immunol."},{"key":"34895_CR2","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718\u2013724 (2020).","journal-title":"Science"},{"key":"34895_CR3","doi-asserted-by":"publisher","unstructured":"Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science https:\/\/doi.org\/10.1126\/science.abd4570 (2020).","DOI":"10.1126\/science.abd4570"},{"key":"34895_CR4","doi-asserted-by":"publisher","unstructured":"Bastard, P. et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science https:\/\/doi.org\/10.1126\/science.abd4585 (2020).","DOI":"10.1126\/science.abd4585"},{"key":"34895_CR5","doi-asserted-by":"publisher","first-page":"eabl4340","DOI":"10.1126\/sciimmunol.abl4340","volume":"6","author":"P Bastard","year":"2021","unstructured":"Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 6, eabl4340 (2021).","journal-title":"Sci. Immunol."},{"key":"34895_CR6","doi-asserted-by":"publisher","unstructured":"Zhang, Q. & Bastard, P. COVID Human Genetic Effort, Cobat, A. & Casanova, J.-L. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature https:\/\/doi.org\/10.1038\/s41586-022-04447-0 (2022).","DOI":"10.1038\/s41586-022-04447-0"},{"key":"34895_CR7","doi-asserted-by":"publisher","first-page":"e2200413119","DOI":"10.1073\/pnas.2200413119","volume":"119","author":"J Manry","year":"2022","unstructured":"Manry, J. et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc. Natl Acad. Sci. USA 119, e2200413119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"34895_CR8","doi-asserted-by":"publisher","first-page":"eabl4348","DOI":"10.1126\/sciimmunol.abl4348","volume":"6","author":"T Asano","year":"2021","unstructured":"Asano, T. et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci. Immunol. 6, eabl4348 (2021).","journal-title":"Sci. Immunol"},{"key":"34895_CR9","doi-asserted-by":"publisher","unstructured":"WHO Solidarity Trial Consortium et al. Repurposed antiviral drugs for Covid-19\u2014Interim WHO Solidarity Trial results. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2023184 (2020).","DOI":"10.1056\/NEJMoa2023184"},{"key":"34895_CR10","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S2213-2600(21)00384-2","volume":"9","author":"AC Kalil","year":"2021","unstructured":"Kalil, A. C. et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 9 1365-1376. (2021).","journal-title":"Lancet Respir. Med"},{"key":"34895_CR11","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","volume":"184","author":"JL Schultze","year":"2021","unstructured":"Schultze, J. L. & Aschenbrenner, A. C. COVID-19 and the human innate immune system. Cell 184, 1671\u20131692 (2021).","journal-title":"Cell"},{"key":"34895_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","volume":"584","author":"C Lucas","year":"2020","unstructured":"Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463\u2013469 (2020).","journal-title":"Nature"},{"key":"34895_CR13","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1126\/science.abc3545","volume":"369","author":"A Broggi","year":"2020","unstructured":"Broggi, A. et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science 369, 706\u2013712 (2020).","journal-title":"Science"},{"key":"34895_CR14","doi-asserted-by":"publisher","unstructured":"Kr\u00e4mer, B. et al. Early IFN-\u03b1 signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity S1074761321003654 https:\/\/doi.org\/10.1016\/j.immuni.2021.09.002 (2021).","DOI":"10.1016\/j.immuni.2021.09.002"},{"key":"34895_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03558-w","volume":"25","author":"F Venet","year":"2021","unstructured":"Venet, F. et al. Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome. Crit. Care 25, 140 (2021).","journal-title":"Crit. Care"},{"key":"34895_CR16","doi-asserted-by":"publisher","first-page":"eabg9873","DOI":"10.1126\/sciimmunol.abg9873","volume":"6","author":"RS Thwaites","year":"2021","unstructured":"Thwaites, R. S. et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci. Immunol. 6, eabg9873 (2021).","journal-title":"Sci. Immunol"},{"key":"34895_CR17","doi-asserted-by":"publisher","first-page":"eabd1554","DOI":"10.1126\/sciimmunol.abd1554","volume":"5","author":"JS Lee","year":"2020","unstructured":"Lee, J. S. et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci. Immunol. 5, eabd1554 (2020).","journal-title":"Sci. Immunol"},{"key":"34895_CR18","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, e9 (2020).","journal-title":"Cell"},{"key":"34895_CR19","unstructured":"Galbraith, M. D. et al. Specialized interferon ligand action in COVID-19. Preprint at medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2021.07.29.21261325v1 (2021)."},{"key":"34895_CR20","doi-asserted-by":"publisher","first-page":"e2111600119","DOI":"10.1073\/pnas.2111600119","volume":"119","author":"J Schuhenn","year":"2022","unstructured":"Schuhenn, J. et al. Differential interferon-\u03b1 subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection. PNAS 119, e2111600119 (2022).","journal-title":"PNAS"},{"key":"34895_CR21","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1016\/j.cell.2021.08.016","volume":"184","author":"B Sposito","year":"2021","unstructured":"Sposito, B. et al. The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell. 184, 4953\u20134968.e16 (2021).","journal-title":"Cell"},{"key":"34895_CR22","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41590-021-01028-7","volume":"22","author":"N Smith","year":"2021","unstructured":"Smith, N. et al. Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. Nat. Immunol. 22, 1428\u20131439 (2021).","journal-title":"Nat. Immunol."},{"key":"34895_CR23","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3389\/fimmu.2021.657363","volume":"12","author":"RP da Silva","year":"2021","unstructured":"da Silva, R. P., Gon\u00e7alves, J. I. B., Zanin, R. F., Schuch, F. B. & de Souza, A. P. D. Circulating Type I interferon levels and COVID-19 severity: a systematic review and meta-analysis. Front. Immunol. 12, 1717 (2021).","journal-title":"Front. Immunol."},{"key":"34895_CR24","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1084\/jem.20161451","volume":"214","author":"MP Rodero","year":"2017","unstructured":"Rodero, M. P. et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J. Exp. Med. 214, 1547\u20131555 (2017).","journal-title":"J. Exp. Med."},{"key":"34895_CR25","doi-asserted-by":"publisher","unstructured":"Bondet, V. et al. Differential levels of IFN\u03b1 subtypes in autoimmunity and viral infection. Cytokine 155533 https:\/\/doi.org\/10.1016\/j.cyto.2021.155533 (2021).","DOI":"10.1016\/j.cyto.2021.155533"},{"key":"34895_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.clim.2017.09.019","volume":"183","author":"D Duffy","year":"2017","unstructured":"Duffy, D. et al. Standardized whole blood stimulation improves immunomonitoring of induced immune responses in multi-center study. Clin. Immunol. 183, 325\u2013335 (2017).","journal-title":"Clin. Immunol."},{"key":"34895_CR27","doi-asserted-by":"publisher","unstructured":"Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in Covid-19. Nature 1\u20131 https:\/\/doi.org\/10.1038\/s41586-020-03065-y (2020).","DOI":"10.1038\/s41586-020-03065-y"},{"key":"34895_CR28","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41590-021-00870-z","volume":"22","author":"H Flament","year":"2021","unstructured":"Flament, H. et al. Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity. Nat. Immunol. 22, 322\u2013335 (2021).","journal-title":"Nat. Immunol."},{"key":"34895_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jaci.2020.04.029","volume":"146","author":"S Trouillet-Assant","year":"2020","unstructured":"Trouillet-Assant, S. et al. Type I IFN immunoprofiling in COVID-19 patients. J. Allergy Clin. Immunol. 146, 206\u2013208.e2 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"34895_CR30","doi-asserted-by":"publisher","unstructured":"Dorgham, K. et al. Distinct cytokine profiles associated with COVID-19 severity and mortality. J. Allergy Clin. Immunol. S0091674921006515 https:\/\/doi.org\/10.1016\/j.jaci.2021.03.047 (2021).","DOI":"10.1016\/j.jaci.2021.03.047"},{"key":"34895_CR31","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1126\/science.abc6261","volume":"369","author":"PS Arunachalam","year":"2020","unstructured":"Arunachalam, P. S. et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 369, 1210\u20131220 (2020).","journal-title":"Science"},{"key":"34895_CR32","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1084\/jem.20111680","volume":"208","author":"J Manry","year":"2011","unstructured":"Manry, J. et al. Evolutionary genetic dissection of human interferons. J. Exp. Med. 208, 2747\u20132759 (2011).","journal-title":"J. Exp. Med."},{"key":"34895_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06519-4","volume":"21","author":"C Iturriaga","year":"2021","unstructured":"Iturriaga, C. et al. A cluster randomized trial of interferon \u00df\u22121a for the reduction of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19). BMC Infect. Dis. 21, 814 (2021).","journal-title":"BMC Infect. Dis."},{"key":"34895_CR34","doi-asserted-by":"publisher","unstructured":"Bastard, P. et al. Interferon-\u03b2 therapy in a patient with incontinentia pigmenti and autoantibodies against Type I IFNs infected with SARS-CoV-2. J. Clin. Immunol. 1\u20133 (2021) https:\/\/doi.org\/10.1007\/s10875-021-01023-5.","DOI":"10.1007\/s10875-021-01023-5"},{"key":"34895_CR35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.it.2021.10.009","volume":"42","author":"N Jouvenet","year":"2021","unstructured":"Jouvenet, N., Goujon, C. & Banerjee, A. Clash of the titans: interferons and SARS-CoV-2. Trends Immunol. 42, 1069\u20131072 (2021).","journal-title":"Trends Immunol."},{"key":"34895_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1084\/jem.20201387","volume":"218","author":"F Onodi","year":"2021","unstructured":"Onodi, F. et al. SARS-CoV-2 induces human plasmacytoid pre-dendritic cell diversification via UNC93B and IRAK4. J. Exp. Med. 218, 4 (2021).","journal-title":"J. Exp. Med."},{"key":"34895_CR37","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1111\/j.1537-2995.2006.00976.x","volume":"46","author":"MER Darnell","year":"2006","unstructured":"Darnell, M. E. R. & Taylor, D. R. Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products. Transfusion 46, 1770\u20131777 (2006).","journal-title":"Transfusion"},{"key":"34895_CR38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.immuni.2014.03.002","volume":"40","author":"D Duffy","year":"2014","unstructured":"Duffy, D. et al. Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli. Immunity 40, 436\u2013450 (2014).","journal-title":"Immunity"},{"key":"34895_CR39","doi-asserted-by":"publisher","first-page":"E488","DOI":"10.1073\/pnas.1714765115","volume":"115","author":"B Piasecka","year":"2018","unstructured":"Piasecka, B. et al. Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges. Proc. Natl Acad. Sci. USA 115, E488\u2013E497 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"34895_CR40","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1016\/j.celrep.2016.08.011","volume":"16","author":"A Urrutia","year":"2016","unstructured":"Urrutia, A. et al. Standardized whole-blood transcriptional profiling enables the deconvolution of complex induced immune responses. Cell Rep. 16, 2777\u20132791 (2016).","journal-title":"Cell Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34895-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34895-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34895-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T16:38:23Z","timestamp":1669394303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34895-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["34895"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-34895-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1685544\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]},"assertion":[{"value":"28 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L.C. is an inventor on patent application PCT\/US2021\/042741, filed 22 July 2021, submitted by The Rockefeller University, which covers diagnosis of, susceptibility to, and treatment of viral disease and viral vaccines, including COVID-19 and vaccine-associated diseases. O.S. is an inventor on provisional patent no. US 63\/020,063 entitled \u201cS-Flow: a FACS-based assay for serological analysis of SARS-CoV2 infection\u201d submitted by Institut Pasteur. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Researchers involved in identification, recruitment, and sampling of patients in the clinical centers in Ireland and France have been included as co-authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Inclusion and Ethics statement"}}],"article-number":"7254"}}